Catalog No.
DHD10402
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Folate receptor alpha, FOLR, FOLR1, Adult folate-binding protein, Folate receptor 1, FR-alpha, KB cells FBP, FBP, Ovarian tumor-associated antigen MOv18, Folate receptor, adult
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P15328
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
M9346A, IMGN853, M9346A-sulfo-SPDB-DM4, CAS: 1453084-36-0
Clone ID
Mirvetuximab
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer, PMID: 32081463
Ocular Toxicity of Mirvetuximab, PMID: 30379722
Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer, PMID: 32674207
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer, PMID: 29098867
Exploiting the folate receptor α in oncology, PMID: 32152484
Antibodies to watch in 2019, PMID: 30516432
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer, PMID: 32984932
Review of Immune Therapies Targeting Ovarian Cancer, PMID: 30430276
New treatments in ovarian cancer, PMID: 29232465
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine, PMID: 30413525
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer, PMID: 29424243
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer, PMID: 30093227
Folate Receptor α-Targeted 89 Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer, PMID: 31369274
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models, PMID: 27889646
Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples, PMID: 28534292
Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics, PMID: 31098752
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors, PMID: 25904506
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors, PMID: 28440955
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study, PMID: 28029313
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine, PMID: 28843653
Antibody-drug conjugates for ovarian cancer: current clinical development, PMID: 30531606
Antibody-drug conjugates for the treatment of ovarian cancer, PMID: 32463296
Antibody-drug conjugates in gynecologic malignancies, PMID: 30929824
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I, PMID: 33667670
Antibodies to watch in 2018, PMID: 29300693
Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments, PMID: 29116596
Novel therapeutics: response and resistance in ovarian cancer, PMID: 31462544
Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors, PMID: 30585545
Novel antibody-drug conjugates: current and future roles in gynecologic oncology, PMID: 32618744
Highlights of the NCCN Oncology Research Program, PMID: 30659135
Significant Activity for ADC in Ovarian Cancer, PMID: 34140289
Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast, PMID: 30268765
Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer, PMID: 27797594
In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers, PMID: 29440294
Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer, PMID: 33812984
For research use only. Not for human or drug use.
